Status:
UNKNOWN
Lp(a) With CCTA Assessed Parameters and Clinical Outcomes
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Brief Summary
Lipoprotein(a) \[Lp(a)\] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HR...
Eligibility Criteria
Inclusion
- Patients with Lp(a) meaured within 1 week of CCTA examination.
Exclusion
- unstable angina pectoris
- acute myocardial infarction
- New York Heart Association class III-IV heart failure
- with a history of bypass surgery
- active infection
- respiratory failure
- chronic kidney disease (estimated glomerular filtration rate \[eGFR\] \<60 ml/min/1.73 m2)
- liver dysfunction (liver enzyme \>3 upper reference limit \[URL\] or bilirubin \>2 URL)
- malignancy
- systemic connective tissue disease
- poor CCTA imaging quality not suitable for analysis
- other situations not suitable for the study
Key Trial Info
Start Date :
March 20 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 30 2022
Estimated Enrollment :
378 Patients enrolled
Trial Details
Trial ID
NCT05323227
Start Date
March 20 2016
End Date
May 30 2022
Last Update
April 12 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Zhongshan Hospital
Shanghai, China